NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sitryx

Sitryx

Private
OxfordHealthcare & Life Scienceshttps://www.sitryx.com/

Last Round

Series A

Extension

Sep 27, 2023

Total Funding Raised

$89M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sitryx is a biopharmaceutical company that develops disease-modifying therapeutics in immuno-oncology and immuno-inflammation by regulating cell metabolism.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

immunometabolismimmunometabolic medicinessmall-molecule drugsoral therapiesautoimmune disease therapeuticsinflammatory disease therapeuticsdrug discovery platformbiopharmapharmaceutical licensingpharma partnershipsbiotech R&Ddrug pipeline developmentpreclinical developmentdisease-modifying therapiesPKM2 inhibitorGLS1 inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sitryx Comparables

Compare Sitryx with similar companies based on industry and business-model similarity.

Sitryx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
META Pharmaceuticals Inc.
82%
Lmito Therapeutics
79%
Aclaris Therapeutics
76%

Sitryx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 27, 2023
Corporate FundingMar 31, 2020
Corporate FundingMar 1, 2020
Series AOct 8, 2018

Key People

Founding team and executive leadership

Iain Kilty

Chief Executive Officer

Executive Team

Adam Mostafa

Chief Financial Officer

Executive Team

Ben Stephens

Chief Operating Officer

Executive Team

Sitryx Investors

Notable investors and investment history

Sitryx investors
InvestorRounds
SV Health InvestorsSeed, Series A Extension, Series A
Oxford Science EnterprisesSeries A Extension
Oxford Science EnterprisesSeries A Extension
Sofinnova PartnersSeries A Extension, Series A
Longwood FundSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Lead glutaminase-1 (GLS1) inhibitor nominated for development.

  • Nov 12, 2025

    Presented preclinical data at the 6th Inflammatory Skin Disease Summit.

Sitryx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sitryx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sitryx's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range48
Year Founded2018
Last FundingSep 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.